OBJECTIVES: Identify patient and clinical characteristics in the pressure ulcer (PU) population and examine patterns of enzymatic debridement utilization. METHODS: Retrospective, de-identified electronic medical records from 2007-2013 were extracted from the Intellicure Limited Data Set (I-LDS). The I-LDS extracts records from 96 hospital-based outpatient wound centers. Patient, wound and encounter level characteristics were examined. Treatment of interest was enzymatic debridement with clostridial collagenase ointment (CCO).   RESULTS: A total of 9,203 patients, 20,358 wounds, and 149,680 encounters for PU were identified. The majority of patients was female (51.0%), Caucasian (70.0%), and reported Medicare as their primary insurance (59.6%). Average age was 67.4 (SD=19.5) and average number of physician visits was 11.3 (SD=14.9). Mean wound surface area was 8.8 cm (SD=30.3). Overall average wound duration was 4.3 months (SD=16.6). Of the 20,358 wounds, approximately 19.8 % received CCO (n=4,022). The majority of wounds treated with CCO were Stage III and IV (60.1% and 29.6%, respectively). Wounds treated with CCO had significantly more (p<0.001) debridements of all methods (4.8, SD=5.9) relative to the overall population (3.7, SD=6.3). Problems treated with CCO were significantly more likely (p<0.0001) to have an infection (65.3%) compared to the overall PU population (51.5%). Average number of visits where CCO was administered was 7.4 (SD=5.9) and the average days of use with CCO was 53.3 days (SD=58.0). Average number of CCO tubes used by patients was 2.2 (SD=0.6). Mean days in service for CCO-treated wounds was 127.9 (SD=159.8), which was significantly higher compared to days in service for non-CCO treated wounds (98.9, SD=157.7).    CONCLUSIONS: Wounds treated with CCO had substantially longer days in service, more likely to receive debridement of all methods, and more likely to be infected relative to the overall PU population. Results from this analysis indicate that healthcare providers are using CCO in Stage III and IV PUs.